Tessera Therapeutics

Tessera Therapeutics is a pioneering company in the life sciences sector, specializing in Gene Writing technology. This groundbreaking biotechnology provides researchers and healthcare professionals with the capability to write both small and large therapeutic instructions into the genome, addressing diseases at their root cause. Gene Writing has the promise to become a distinct category within genetic medicine, advancing beyond recent accomplishments in gene therapy and gene editing by overcoming significant limitations in their application, effectiveness, and scope. Founded in 2018, Tessera Therapeutics secured a significant $300.00M Series C investment on April 19, 2022, with funds coming from March Capital, Flagship Pioneering, Alaska Permanent Fund, Altitude Life Sciences, Cormorant Asset Management, Hanwha Impact Partners, Longevity Vision Fund, SoftBank Vision Fund, SALT Fund, and Artis Ventures (AV). Tessera Therapeutics' ambition to rewrite the genome and cure diseases at their source has attracted significant attention and investment from leading organizations dedicated to enhancing human health and sustainability.